AMAG Pharmaceuticals, Inc. (AMAG) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 377,479 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,452 shares during the quarter. Geode Capital Management LLC owned 1.07% of AMAG Pharmaceuticals worth $5,001,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. raised its position in AMAG Pharmaceuticals by 19.5% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 778,488 shares of the specialty pharmaceutical company’s stock valued at $10,316,000 after purchasing an additional 126,780 shares during the period. Schwab Charles Investment Management Inc. increased its position in shares of AMAG Pharmaceuticals by 5.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 447,363 shares of the specialty pharmaceutical company’s stock worth $5,928,000 after acquiring an additional 22,488 shares during the period. Spark Investment Management LLC purchased a new stake in shares of AMAG Pharmaceuticals during the fourth quarter worth $1,547,000. Systematic Financial Management LP increased its position in shares of AMAG Pharmaceuticals by 31.9% during the fourth quarter. Systematic Financial Management LP now owns 111,535 shares of the specialty pharmaceutical company’s stock worth $1,478,000 after acquiring an additional 26,945 shares during the period. Finally, Rhumbline Advisers increased its position in shares of AMAG Pharmaceuticals by 12.8% during the fourth quarter. Rhumbline Advisers now owns 84,341 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after acquiring an additional 9,576 shares during the period.

How to Become a New Pot Stock Millionaire

Shares of AMAG stock opened at $20.80 on Thursday. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.74 and a quick ratio of 1.60. The firm has a market cap of $714.16, a P/E ratio of -3.64 and a beta of 0.09. AMAG Pharmaceuticals, Inc. has a 12 month low of $11.93 and a 12 month high of $24.85.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.68. The firm had revenue of $158.30 million during the quarter, compared to the consensus estimate of $158.84 million. AMAG Pharmaceuticals had a negative net margin of 32.66% and a positive return on equity of 0.96%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.31) earnings per share. sell-side analysts anticipate that AMAG Pharmaceuticals, Inc. will post -3.25 earnings per share for the current year.

A number of analysts have recently weighed in on the company. BidaskClub raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. B. Riley upped their price objective on AMAG Pharmaceuticals from $16.00 to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 14th. Jefferies Group lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the stock from $21.00 to $20.00 in a research report on Monday, March 5th. Piper Jaffray reaffirmed a “hold” rating and set a $20.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, March 1st. Finally, Morgan Stanley upped their price objective on AMAG Pharmaceuticals from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $23.91.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2018/04/19/amag-pharmaceuticals-inc-amag-shares-bought-by-geode-capital-management-llc.html.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply